Advertisement

Medical Oncology

, 33:67 | Cite as

ABO blood groups in relation to breast carcinoma incidence and associated prognostic factors in Moroccan women

  • S. ZouineEmail author
  • F. Marnissi
  • N. Otmani
  • M. Bennani Othmani
  • M. El Wafi
  • K. Kojok
  • Y. Zaid
  • N. Tahiri Jouti
  • N. Habti
Original Paper

Abstract

The association between blood groups ABO and different types of diseases was established in several previous studies. Our aim was to seek the possible association between the ABO blood group and breast cancer-associated prognostic factors. The Chi-squared analytic test was used to compare phenotypic ABO distribution among Moroccan blood donors and 442 cases of women suffering from breast carcinoma with archived files in Maternity Ward of University Hospital C.H.U Ibn Rochd between 2008 and 2011. High incidence of breast carcinoma was observed in blood type B patients (p < 0.05). Blood type B was associated with breast carcinomas overexpressing human epidermal growth factor receptor HER2 (p < 0.05) and high risk of cancer at age over 70 years (p < 0.001). Blood type A was associated with high risk of cancer among women younger than 35 years old. Blood type A and AB were associated with high incidence of lymph node metastasis (p < 0.05). Multivariate analysis has shown correlation between O blood type and estrogen receptor-positive tumor. Patients with blood group A, B, and AB were more likely to develop aggressive breast carcinoma. Further follow-up studies are necessary to clarify the role of ABH antigens in the progression of breast carcinoma.

Keywords

ABO blood group Breast carcinoma Age at diagnosis Human epidermal growth factor receptor 2 Lymph node metastasis Estrogen receptor 

Abbreviations

CHU

Centre Hospitalier Universitaire

ER

Estrogen receptor

HER2

Human epidermal growth factor receptor 2

PR

Progesterone receptor

SBR

Scraff Bloom and Richardson histological grading

SICAM-1

Soluble intercellular adhesion molecule-1

SNP

Single nucleotide polymorphism

TNF-α

Tumor necrosis factor-alpha

VWF

Von Willebrand factor

Notes

Acknowledgments

We are extremely grateful to Pr S. Zamiati who has facilitated us access to Pathology Department and Pr M. Matar who has facilitated us access to Maternity Ward L 9 C.H.U Ibn Rochd Casablanca. We thank all the team of Pathology Department C.H.U Ibn Rochd in Casablanca: Pr S. Benayad; residents; secretary; and technicians for their kind helping and encouragement.

Author contributions

SZ, FM, MEW, NTJ, and NH participated in the design of the study. SZ and NH interpreted results and wrote the paper. NO and MBO performed the statistical analysis. All authors have read and approved the final version of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare having no conflict of interests.

References

  1. 1.
    Eastlund T. The histo-blood group ABO system and tissue transplantation. Transfusion. 1998;38(10):975–88.CrossRefPubMedGoogle Scholar
  2. 2.
    Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS. 2000;108(1):1–28.CrossRefPubMedGoogle Scholar
  3. 3.
    Yamamoto F, et al. Molecular genetic basis of the histo-blood group ABO system. Nature. 1990;345(6272):229–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Yamamoto F, et al. Cloning and characterization of DNA complementary to human UDP-GalNAc: Fuc alpha 1—2Gal alpha 1—3GalNAc transferase (histo-blood group A transferase) mRNA. J Biol Chem. 1990;265(2):1146–51.PubMedGoogle Scholar
  5. 5.
    Simoneau M, et al. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene. 2000;19(54):6317–23.CrossRefPubMedGoogle Scholar
  6. 6.
    Baudis M. Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer. 2007;7:226.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Rakosy Z, et al. Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2008;182(2):116–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Vogel F. Controversy in human genetics. ABO blood groups and disease. Am J Hum Genet. 1970;22(4):464–75.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Costantini M, et al. Role of blood groups as prognostic factors in primary breast cancer. Oncology. 1990;47(4):308–12.CrossRefPubMedGoogle Scholar
  10. 10.
    Mourali N, et al. Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer. 1980;46(12):2741–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Habti N, Nourichafi N, Benchemsi N. ABO polymorphism in blood donors in Morocco. Transfus Clin Biol. 2004;11(2):95–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.CrossRefPubMedGoogle Scholar
  14. 14.
    Annese V, et al. ABO blood groups and cancer of the pancreas. Int J Pancreatol. 1990;6(2):81–8.PubMedGoogle Scholar
  15. 15.
    Su M, et al. Relationship between ABO blood groups and carcinoma of esophagus and cardia in Chaoshan inhabitants of China. World J Gastroenterol. 2001;7(5):657–61.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Aird I, Bentall HH, Roberts JA. A relationship between cancer of stomach and the ABO blood groups. Br Med J. 1953;1(4814):799–801.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Aird I, Lee DR, Roberts JA. ABO blood groups and cancer of oesophagus, cancer of pancreas, and pituitary adenoma. Br Med J. 1960;1(5180):1163–6.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Anderson DE, Haas C. Blood type A and familial breast cancer. Cancer. 1984;54(9):1845–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Pandey M, Gautam A, Shukla VK. ABO and Rh blood groups in patients with cholelithiasis and carcinoma of the gall bladder. BMJ. 1995;310(6995):1639.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Iodice S, et al. ABO blood group and cancer. Eur J Cancer. 2010;46(18):3345–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Ben Q, et al. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case–control study. Int J Cancer. 2011;128(5):1179–86.CrossRefPubMedGoogle Scholar
  22. 22.
    Yuzhalin AE, Kutikhin AG. ABO and Rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of South-East Siberia. Asian Pac J Cancer Prev. 2012;13(10):5091–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Rahbari NN, et al. AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer. 2012;12:319.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Poole EM, et al. ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. Cancer Causes Control. 2012;23(11):1805–10.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wang DS, et al. ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Int J Cancer. 2012;131(2):461–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Wang Z, et al. ABO blood group system and gastric cancer: a case-control study and meta-analysis. Int J Mol Sci. 2012;13(10):13308–21.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Woo SM, et al. Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case–control study. J Korean Med Sci. 2013;28(2):247–51.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Hsiao LT, et al. ABO blood group and the risk of cancer among middle-aged people in Taiwan. Asia Pac J Clin Oncol. 2015;11(4):31–6.CrossRefGoogle Scholar
  29. 29.
    Zhang BL, et al. ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15(11):4643–50.CrossRefPubMedGoogle Scholar
  30. 30.
    Etemadi A, et al. Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study. BMC Med. 2015;13:8.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Vioque J, Walker AM. Pancreatic cancer and ABO blood types: a study of cases and controls. Med Clin (Barc). 1991;96(20):761–4.Google Scholar
  32. 32.
    Torti RA. ABO blood groups and Rh. Antigens in patients with carcinoma of the breast. Med Times. 1963;91:1167–8.PubMedGoogle Scholar
  33. 33.
    Rai S, et al. ABO blood group distribution in carcinoma of the breast. Indian J Cancer. 1970;7(2):135–9.PubMedGoogle Scholar
  34. 34.
    Newell GR, et al. ABO blood groups and cancer. J Natl Cancer Inst. 1974;52(5):1425–30.PubMedGoogle Scholar
  35. 35.
    Munzarova M, et al. Course of breast cancer disease and ABO blood groups. Biomed Pharmacother. 1985;39(9–10):486–9.PubMedGoogle Scholar
  36. 36.
    Dede DS, et al. Blood ABO groups and risk of breast cancer. Med Oncol. 2010;27(4):1433.CrossRefPubMedGoogle Scholar
  37. 37.
    Khalili H, et al. ABO blood group and risk of colorectal cancer. Cancer Epidemiol Biomark Prev. 2011;20(5):1017–20.CrossRefGoogle Scholar
  38. 38.
    Joh HK, Cho E, Choueiri TK. ABO blood group and risk of renal cell cancer. Cancer Epidemiol. 2012;36(6):528–32.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Gates MA, et al. ABO blood group and breast cancer incidence and survival. Int J Cancer. 2012;130(9):2129–37.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Teresa DB, et al. Polymorphisms of Lewis and Secretor genes are related to breast cancer and metastasis in axillary lymph nodes. Tumour Biol. 2010;31(5):401–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Klimant E, et al. Blood type, hormone receptor status, HER2/neu status, and survival in breast cancer: a retrospective study exploring relationships in a phenotypically well-defined cohort. Clin Med Res. 2011;9(3–4):111–8.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998;3(4):237–52.PubMedGoogle Scholar
  43. 43.
    Holdsworth PJ, et al. Blood group as a prognostic indicator in breast cancer. Br Med J (Clin Res Ed). 1985;290(6469):671–3.CrossRefGoogle Scholar
  44. 44.
    Marionneau S, Le Moullac-Vaidye B, Le Pendu J. Expression of histo-blood group A antigen increases resistance to apoptosis and facilitates escape from immune control of rat colon carcinoma cells. Glycobiology. 2002;12(12):851–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.CrossRefPubMedGoogle Scholar
  46. 46.
    Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361–71.CrossRefPubMedGoogle Scholar
  48. 48.
    Melzer D, et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet. 2008;4(5):e1000072.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today. 1993;14(10):506–12.CrossRefPubMedGoogle Scholar
  50. 50.
    Pare G, et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6578 women. PLoS Genet. 2008;4(7):e1000118.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Barbalic M, et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet. 2010;19(9):1863–72.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Ruggeri ZM. Structure and function of von Willebrand factor: relationship to von Willebrand’s disease. Mayo Clin Proc. 1991;66(8):847–61.CrossRefPubMedGoogle Scholar
  53. 53.
    Gordon JL, et al. Plasma von Willebrand factor in connective tissue disease. Ann Rheum Dis. 1987;46(6):491–2.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Franchini M, et al. von Willebrand factor and cancer: a renewed interest. Thromb Res. 2013;131(4):290–2.CrossRefPubMedGoogle Scholar
  55. 55.
    Gill JC, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691–5.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • S. Zouine
    • 1
    • 2
    Email author
  • F. Marnissi
    • 3
  • N. Otmani
    • 4
  • M. Bennani Othmani
    • 4
  • M. El Wafi
    • 1
    • 2
  • K. Kojok
    • 5
  • Y. Zaid
    • 5
  • N. Tahiri Jouti
    • 6
  • N. Habti
    • 1
    • 2
  1. 1.Laboratory of Biotechnology and Experimental Medicine, Faculty of Medicine and Pharmacy CasablancaHassan II University of CasablancaCasablancaMorocco
  2. 2.Laboratory of Hematology, Cellular and Genetic Engineering, Faculty of Medicine and Pharmacy CasablancaHassan II University of CasablancaCasablancaMorocco
  3. 3.Pathology DepartmentUniversity Hospital Ibn Rochd CasablancaCasablancaMorocco
  4. 4.Laboratory of Medical Informatics, Faculty of Medicine and Pharmacy of CasablancaHassan II University of CasablancaCasablancaMorocco
  5. 5.Laboratory of Thrombosis and HemostasisMontreal Heart InstituteMontrealCanada
  6. 6.Pathology Laboratory, Faculty of Medicine and Pharmacy of CasablancaHassan II University of CasablancaCasablancaMorocco

Personalised recommendations